Zobrazeno 1 - 10
of 222
pro vyhledávání: '"Joos V, Lebesque"'
Autor:
Marnix G. Witte, Luca Incrocci, Shafak Aluwini, Floris J. Pos, Ruud C. Wortel, Wilma D. Heemsbergen, Joos V. Lebesque, Uulke A. van der Heide
Publikováno v:
International Journal of Radiation Oncology Biology Physics, 95(2), 680-689. Elsevier Inc.
Purpose: Technical developments in the field of external beam radiation therapy (RT) enabled the clinical introduction of image guided intensity modulated radiation therapy (IG-IMRT), which improved target conformity and allowed reduction of safety m
Autor:
Marcel van Herk, Marnix G. Witte, Luca Incrocci, Uulke A. van der Heide, Joos V. Lebesque, Wilma D. Heemsbergen, Ruud C. Wortel, Floris J. Pos
Publikováno v:
Radiotherapy and Oncology, 117(3), 515-520. Elsevier Ireland Ltd
Radiotherapy and oncology, 117(3), 515-520. Elsevier Ireland Ltd
Radiotherapy and oncology, 117(3), 515-520. Elsevier Ireland Ltd
Background and purpose: We evaluated dose distributions in the anorectum and its relation to acute gastrointestinal toxicities using dose surface maps in an image-guided (IG) IMRT and 3D-conformal radiotherapy (3D-CRT) population. Material and method
Autor:
Uulke A. van der Heide, Wilma D. Heemsbergen, Joos V. Lebesque, Floris J. Pos, Marcel van Herk, Marnix G. Witte, Luca Incrocci, Ruud C. Wortel
Publikováno v:
International journal of radiation oncology, biology, physics, 91(4), 737-744. Elsevier Inc.
International Journal of Radiation Oncology Biology Physics, 91(4), 737-744. Elsevier Inc.
International Journal of Radiation Oncology Biology Physics, 91(4), 737-744. Elsevier Inc.
Purpose: Image-guided intensity modulated radiation therapy (IG-IMRT) allows significant dose reductions to organs at risk in prostate cancer patients. However, clinical data identifying the benefits of IG-IMRT in daily practice are scarce. The purpo
Publikováno v:
Radiotherapy and Oncology. 127:S501-S502
Autor:
A. Scheenstra, Jan-Jakob Sonke, Eugène M.F. Damen, Maddalena Rossi, Joos V. Lebesque, José Belderbos
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 88:224-228
Purpose To estimate the α/β ratio for which the dose-dependent lung perfusion reductions for stereotactic body radiation therapy (SBRT) and conventionally fractionated radiation therapy (CFRT) are biologically equivalent. Methods and Materials The
Autor:
José Belderbos, Jan-Jakob Sonke, Joos V. Lebesque, Maddalena Rossi, A. Scheenstra, Eugène M.F. Damen
Publikováno v:
Radiotherapy and Oncology. 107:398-402
To model the local dose-effect relation for lung perfusion reduction in lung cancer patients treated with stereotactic body radiotherapy (SBRT).Forty-two patients having upper-lobe peripheral tumours5 cm treated with SBRT (3×18 Gy) underwent single-
Autor:
Joos V. Lebesque, José Belderbos, Gerben R. Borst, Andrew Jackson, Ellen Yorke, Fan Liu, Kenneth E. Rosenzweig
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 85:182-189
Purpose To demonstrate the use of generalized equivalent uniform dose (gEUD) atlas for data pooling in radiation pneumonitis (RP) modeling, to determine the dependence of RP on gEUD, to study the consistency between data sets, and to verify the incre
Autor:
Jasper Nijkamp, Michel M. van den Heuvel, Joos V. Lebesque, Margriet Kwint, José Belderbos, Maddalena Rossi, Wilma Uyterlinde, Jan-Jakob Sonke, Wouter V. Vogel
Publikováno v:
Aarhus University
Nijkamp, J, Rossi, M, Lebesque, J, Belderbos, J, van den Heuvel, M, Kwint, M, Uyterlinde, W, Vogel, W & Sonke, J J 2013, ' Relating acute esophagitis to radiotherapy dose using FDG-PET in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer ', Radiotherapy & Oncology, vol. 106, no. 1, pp. 118-123 .
Nijkamp, J, Rossi, M, Lebesque, J, Belderbos, J, van den Heuvel, M, Kwint, M, Uyterlinde, W, Vogel, W & Sonke, J J 2013, ' Relating acute esophagitis to radiotherapy dose using FDG-PET in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer ', Radiotherapy & Oncology, vol. 106, no. 1, pp. 118-123 .
To correlate radiotherapy (RT) dose to acute esophagitis (AE) by means of FDG-PET scans acquired after concurrent chemo-radiotherapy (cCRT) for locally advanced non-small-cell lung cancer (NSCLC).Patients treated with 24 × 2.75 Gy were selected on p
Autor:
A. de Josien Bois, Hiroki Shirato, Gerben R. Borst, Jan-Jakob Sonke, Gerard Bengua, Masayori Ishikawa, Michael Hauptmann, Rikiya Onimaru, Joos V. Lebesque, Jasper Nijkamp
Publikováno v:
Aarhus University
Borst, G R, Ishikawa, M, Nijkamp, J, Hauptmann, M, Shirato, H, Bengua, G, Onimaru, R, de Josien Bois, A, Lebesque, J V & Sonke, J J 2010, ' Radiation pneumonitis after hypofractionated radiotherapy: evaluation of the LQ(L) model and different dose parameters ', International Journal of Radiation Oncology, Biology, Physics, vol. 77, no. 5, pp. 1596-1603 .
Borst, G R, Ishikawa, M, Nijkamp, J, Hauptmann, M, Shirato, H, Bengua, G, Onimaru, R, de Josien Bois, A, Lebesque, J V & Sonke, J J 2010, ' Radiation pneumonitis after hypofractionated radiotherapy: evaluation of the LQ(L) model and different dose parameters ', International Journal of Radiation Oncology, Biology, Physics, vol. 77, no. 5, pp. 1596-1603 .
Purpose To evaluate the linear quadratic (LQ) model for hypofractionated radiotherapy within the context of predicting radiation pneumonitis (RP) and to investigate the effect if a linear (L) model in the high region (LQL model) is used. Methods and
Autor:
Marcel van Herk, Floris J. Pos, R. Bohoslavsky, Wilma D. Heemsbergen, Abrahim Al-Mamgani, Marnix G. Witte, Joos V. Lebesque
Publikováno v:
International Journal of Radiation Oncology Biology Physics, 77(1), 131-138. Elsevier Inc.
International journal of radiation oncology, biology, physics, 77(1), 131-138. Elsevier Inc.
International journal of radiation oncology, biology, physics, 77(1), 131-138. Elsevier Inc.
Purpose: For prostate cancer patients at risk for subclinical spread of the disease, we investigated whether incidental dose outside the target was associated with tumor control. Methods and Materials: We selected 352 intermediate-risk (mainly T2b-T3